» Articles » PMID: 38190135

Peritoneal Dialysis Care for People with Diabetes, Polycystic Kidney Disease, or Advanced Liver Disease

Overview
Specialty Nephrology
Date 2024 Jan 8
PMID 38190135
Authors
Affiliations
Soon will be listed here.
Abstract

People treated with peritoneal dialysis (PD) often have complicating conditions that require careful management. Three such conditions are reviewed in this article-diabetes mellitus, polycystic kidney disease, and chronic liver disease. Each of these conditions requires an understanding of both its effect on the delivery of the PD and the effect of the PD on the condition itself. In diabetes, glucose absorption from the dialysate complicates metabolic control and affects salt and water management and patient outcome. There is particular benefit in clinical care being delivered through a multidisciplinary team that involves both kidney and diabetes experts. In relation to polycystic kidney disease, a key issue is the potential for increased intraperitoneal pressure due to the combined effect of the enlarged polycystic organs and the presence of the dialysis solution, and therefore, the PD prescription requires to be managed with a particular focus on limiting that pressure. For patients with liver disease, key issues include nutritional support because PD can add to protein losses already consequent on the liver disease itself. Considered approaches are required to manage ascites and reduce infection risk and the potential for hernias and leaks to develop. Mortality in this group is unfortunately high-however, PD may present a better management option than hemodialysis in many patients-particularly in those where the liver disease is complicated by low BP, clotting abnormalities, or troublesome ascites. Overall, the choice to use PD in patients with these complicating conditions should be based on shared decision making with the patient and their family members informed by high-quality information in which risks, benefits, and management strategies are clearly presented.

References
1.
Abe M, Hamano T, Hoshino J, Wada A, Nakai S, Masakane I . Glycemic control and survival in peritoneal dialysis patients with diabetes: A 2-year nationwide cohort study. Sci Rep. 2019; 9(1):3320. PMC: 6397316. DOI: 10.1038/s41598-019-39933-5. View

2.
Hahr A, Molitch M . Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022. Am J Kidney Dis. 2021; 79(5):728-736. DOI: 10.1053/j.ajkd.2021.05.023. View

3.
Van Biesen W, Verger C, Heaf J, Vrtovsnik F, Britto Z, Do J . Evolution Over Time of Volume Status and PD-Related Practice Patterns in an Incident Peritoneal Dialysis Cohort. Clin J Am Soc Nephrol. 2019; 14(6):882-893. PMC: 6556715. DOI: 10.2215/CJN.11590918. View

4.
Morris-Stiff G, Coles G, MOORE R, Jurewicz A, Lord R . Abdominal wall hernia in autosomal dominant polycystic kidney disease. Br J Surg. 1997; 84(5):615-7. View

5.
McCaleb M, Izzo M, Lockwood D . Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest. 1985; 75(2):391-6. PMC: 423502. DOI: 10.1172/JCI111712. View